Coronary CT Angiogram Longevity-Medicine Target Ranges

What a Coronary CT Angiogram Actually Measures

A CCTA uses iodinated contrast and ECG-gated computed tomography to produce three-dimensional images of the coronary lumen and vessel wall. It gives clinicians direct visualization of plaque composition, stenosis severity, and vessel remodeling. Standard cardiac catheterization only images the lumen; CCTA images the wall where plaque lives before it ever narrows the artery.

Lumen Stenosis vs. Plaque Burden

Stenosis is graded on a five-category scale: 0% (no plaque), 1 to 24% (minimal), 25 to 49% (mild), 50 to 69% (moderate), 70 to 99% (severe), and 100% (total occlusion). Conventional cardiology classifies anything below 50% as non-obstructive and generally reassuring. Longevity medicine sets a stricter standard: any detectable atherosclerosis, even 1 to 24% stenosis, represents a disease process that started years earlier and demands intervention.

Plaque Composition Categories

The CT scanner distinguishes plaque by Hounsfield unit (HU) density:

• Calcified plaque (above 130 HU): dense calcium deposits; generally more stable but still predictive of events at high burden.
• Non-calcified plaque (below 30 HU, "soft" or low-attenuation plaque): lipid-rich, vulnerable to rupture.
• Mixed plaque: both calcified and non-calcified components.

The ICONIC study (N=1,764) found that non-calcified plaque volume was a stronger independent predictor of acute coronary syndrome than luminal stenosis alone. [1]

High-Risk Plaque Features

Four features on CCTA are specifically associated with near-term acute coronary events [2]:

1. Low-attenuation plaque (HU <30 on non-contrast, representing lipid-rich necrotic core)
2. Positive remodeling (remodeling index >1.1, meaning the vessel wall has expanded outward to accommodate growing plaque)
3. Napkin-ring sign (a rim of high-attenuation tissue surrounding a low-attenuation core)
4. Spotty calcification (small, punctate calcium deposits within soft plaque)

The presence of two or more of these features on a single lesion identifies what the SCCT 2021 Expert Consensus document calls "high-risk plaque," associated with a major adverse cardiac event (MACE) rate roughly four times higher than lesions without these features. [3]

Longevity-Medicine Target Ranges for CCTA

The conventional goal in clinical cardiology is ruling out obstructive disease. Longevity medicine targets complete absence of atherosclerosis. These are not the same thing. Understanding both thresholds helps patients know what to aim for.

The Optimal Longevity Target: Zero Plaque

The optimal CCTA result for a patient in a longevity-focused program is:

| Parameter | Optimal (Longevity) | Acceptable (Conventional) | |---|---|---| | CAC score | 0 | <100 (low risk) | | Plaque on CCTA | None detected | Non-obstructive (<50% stenosis) | | Low-attenuation plaque | Absent | Not formally graded unless stenosis present | | Positive remodeling | Absent | Not formally graded unless stenosis present | | Napkin-ring sign | Absent | Not routinely reported | | Segment involvement score | 0 | <5 |

A CAC score of 0 combined with no plaque on CCTA has a negative predictive value for obstructive CAD of 96 to 99% and is associated with a 10-year MACE rate below 1% in patients without symptoms. [4] That is the floor, not the ceiling, of what a 45-year-old should aim for.

Why CAC Score Alone Is Not Enough

Coronary artery calcium scoring (CAC, or CACS) is faster, cheaper, and uses less radiation than CCTA. However, it misses all non-calcified plaque entirely. A patient can have a CAC of 0 and still carry a meaningful soft-plaque burden. The PROMISE trial (N=10,003) showed that patients with non-obstructive non-calcified plaque on CCTA had significantly higher event rates than those with truly plaque-free arteries, even when CAC was 0. [5] A full CCTA, not just a calcium score, provides the complete picture.

Segment Involvement Score and Segment Stenosis Score

Beyond single-lesion grading, two composite scores help quantify total plaque burden across all 18 coronary segments:

• Segment Involvement Score (SIS): counts how many of the 18 segments contain any plaque. An SIS of 0 is optimal. An SIS of 5 or above carries a hazard ratio of approximately 3.0 for cardiac death or nonfatal MI compared to SIS of 0 in CONFIRM registry data (N=27,125). [6]
• Segment Stenosis Score (SSS): weights each involved segment by stenosis severity (0 to 3 per segment, maximum 54). An SSS above 5 is considered high burden.

How CCTA Compares to Other Cardiovascular Longevity Tests

CCTA vs. Coronary Artery Calcium Score

CAC is a 10-minute, low-radiation scan (0.5 to 1 mSv) that detects calcified plaque only. CCTA takes 20 to 30 minutes, uses contrast, delivers 1 to 3 mSv, and images both calcified and non-calcified plaque plus the lumen. In a longevity panel, CCTA provides more actionable data. CAC remains a reasonable first-line screen in patients who need risk stratification before committing to CCTA.

CCTA vs. Stress Testing

Exercise stress testing detects ischemia at the functional level, meaning a vessel has to be substantially narrowed before the test turns positive. The PROMISE trial directly compared CCTA to functional stress testing for symptomatic patients with stable chest pain. CCTA detected more obstructive CAD, led to more appropriate preventive therapy initiation, and did not increase downstream testing compared to stress testing. [5] For asymptomatic longevity patients, stress testing adds very little because it will almost always be normal until disease is quite advanced.

CCTA vs. Invasive Coronary Angiography

Catheterization remains the gold standard for precise stenosis measurement before revascularization decisions. For screening and surveillance in asymptomatic or mildly symptomatic patients, however, CCTA carries a Class I recommendation in the 2023 AHA/ACC Chest Pain Guideline for patients with intermediate-to-high pretest probability of obstructive CAD. [7] The 2023 guideline states: "CCTA is recommended for symptomatic patients with stable chest pain and intermediate pretest probability of obstructive CAD to diagnose CAD and guide management." [7]

Interpreting Your CCTA Report: A Practical Walkthrough

The RADS Reporting Structure

Most academic centers and teleradiology platforms now use the CAD-RADS (Coronary Artery Disease Reporting and Data System) 2.0 classification, published by the SCCT and ACR in 2022. [3] Each coronary tree segment is scored and a final CAD-RADS category assigned:

• CAD-RADS 0: No plaque, no stenosis. Optimal longevity result.
• CAD-RADS 1: 1 to 24% stenosis (minimal plaque). Actionable in longevity medicine even if "normal" conventionally.
• CAD-RADS 2: 25 to 49% stenosis (mild, non-obstructive).
• CAD-RADS 3: 50 to 69% stenosis (moderate, obstructive).
• CAD-RADS 4A: 70 to 99% stenosis in one vessel.
• CAD-RADS 4B: Left main or three-vessel disease with severe stenosis.
• CAD-RADS 5: Total occlusion.

Modifiers include "HRP" (high-risk plaque present), "S" (stent), "G" (graft), and "E" (exception, meaning the scan quality limits interpretation of a specific segment).

What to Ask for in the Radiology Report

Request that the report explicitly state:

1. Total plaque volume (mm3) by composition type if software allows quantification.
2. SIS and SSS scores.
3. Presence or absence of each of the four high-risk plaque features per lesion.
4. CAC score derived from the contrast scan (or request a separate pre-contrast CAC run).

Not all radiology groups report all four of these by default. Asking directly, before the scan, increases the yield of the report.

Evidence Base: Key Trials and Their Numbers

SCOT-HEART (N=4,146)

The SCOT-HEART trial randomized patients with stable chest pain to CCTA plus standard care vs. Standard care alone. At 5-year follow-up, the CCTA group had a 41% relative reduction in fatal and nonfatal MI (2.3% vs. 3.9%, P<0.001). [8] The mechanism was earlier detection of non-obstructive plaque, which prompted preventive therapy initiation that standard care missed.

PROMISE Trial (N=10,003)

PROMISE compared CCTA to functional testing (nuclear stress, stress echo, or exercise ECG) in 10,003 stable-chest-pain patients. CCTA diagnosed obstructive CAD in 11% of patients vs. 6% by functional testing. Rates of invasive angiography showing non-obstructive disease were lower in the CCTA arm (3.4% vs. 4.3%), meaning fewer unnecessary catheterizations. [5]

ICONIC (N=1,764)

In ICONIC, baseline CCTA plaque features were compared between patients who later experienced acute coronary syndromes and those who did not. Patients with subsequent ACS had higher non-calcified plaque volume (mean 100 mm3 vs. 47 mm3) and more frequent positive remodeling (38% vs. 17%) at baseline. The odds ratio for ACS with any high-risk plaque feature present was 3.77 (95% CI 2.41 to 5.90). [1]

CONFIRM Registry (N=27,125)

This multinational registry followed 27,125 patients after CCTA for a median of 2.3 years. Obstructive CAD was present in 24.4% of patients. Each one-unit increase in SIS was associated with a 14% increase in the hazard of MACE after adjustment for traditional risk factors. Patients with non-obstructive plaque still had a significantly higher MACE rate than those with completely normal scans. [6]

Clinical Actions Triggered by CCTA Findings

CAD-RADS 0: No Plaque Detected

This result supports rescan in 5 years if baseline risk is low. Preventive focus stays on lifestyle: LDL below 70 mg/dL, blood pressure below 120/80 mmHg, fasting glucose below 100 mg/dL, and non-smoking status. No pharmacological lipid-lowering is required by any guideline for a truly plaque-free, low-risk patient.

CAD-RADS 1 to 2: Non-Obstructive Plaque Present

Conventional cardiology often reassures patients and discharges them at this stage. Longevity medicine initiates aggressive risk reduction: high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg), LDL target below 55 mg/dL, blood pressure optimization, and annual metabolic review. The 2019 ESC/EAS Dyslipidemias Guideline assigns very high cardiovascular risk, and an LDL target of <55 mg/dL, to patients with documented atherosclerosis on imaging. [9]

The guideline states: "In patients at very high risk, an LDL-C goal of <1.4 mmol/L (<55 mg/dL) and a reduction of at least 50% from baseline is recommended." [9]

CAD-RADS 3 to 4: Obstructive Disease

Referral to an interventional cardiologist or cardiac surgeon is appropriate. Functional assessment with fractional flow reserve CT (FFRCT, e.g., HeartFlow analysis) helps determine whether stenosis is hemodynamically significant before catheterization. FFRCT can be ordered as an add-on to the CCTA dataset without a repeat scan.

High-Risk Plaque Features Present

Regardless of the stenosis severity grade, the presence of HRP modifies management. In a patient with CAD-RADS 2 plus HRP, cardiologists often treat more aggressively than a CAD-RADS 3 without HRP, given the rupture risk data from ICONIC. [1] Add-on PCSK9 inhibitor therapy (evolocumab 140 mg every 2 weeks or alirocumab 75 to 150 mg every 2 to 4 weeks) may be considered to bring LDL below 40 mg/dL in patients with HRP features.

Radiation, Contrast, and Safety Considerations

Modern prospective ECG-triggered CCTA delivers 1 to 3 mSv, roughly equivalent to 100 to 300 chest X-rays or about the same as a screening mammogram. Retrospective gating (used when heart rate is irregular or fast) delivers 8 to 18 mSv and is avoided when prospective gating is possible. Beta-blocker premedication (metoprolol 50 to 100 mg oral, given 60 minutes before the scan) lowers heart rate to below 65 bpm, which substantially improves image quality and allows prospective gating.

Iodinated contrast carries a small risk of contrast-induced nephropathy in patients with estimated GFR below 45 mL/min/1.73 m2. A same-day creatinine check is standard before proceeding. Gadolinium is not used in CCTA; iodinated agents such as iohexol or iopamidol are standard.

Frequency and Surveillance Protocol in Longevity Medicine

A reasonable CCTA surveillance schedule for a longevity patient, based on SCCT 2021 consensus and clinical judgment, is:

• CAD-RADS 0, no risk factors: Repeat CCTA or CAC in 5 years.
• CAD-RADS 0, elevated risk factors (LDL >130, hypertension, family history, smoking): Repeat in 3 years.
• CAD-RADS 1 to 2, on statin: Repeat in 2 to 3 years to assess plaque progression or regression.
• CAD-RADS 3 to 4: Managed by cardiology; rescan timing individualized.

Plaque regression on serial CCTA after aggressive statin therapy has been documented in multiple trials. The SATURN trial (N=1,039) compared rosuvastatin 40 mg to atorvastatin 80 mg over 24 months using intravascular ultrasound. Both produced plaque regression; rosuvastatin achieved a mean percent atheroma volume reduction of 0.99% vs. 0.79% for atorvastatin. [10] CCTA-based studies using total plaque volume show similar directional data.